<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>57-AZOLE-ANTIFUNGALS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="AZOLE ANTIFUNGALS" code="J02AC-001" /></DRUG1>
<DRUG2>
<DRUG name="COLCHICINE" rxcui="2683">
<ATC code="M04AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the undesirable effects of the colchicine with potentially fatal consequences</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>57-AZOLE-ANTIFUNGALS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="AZOLE ANTIFUNGALS" code="J02AC-001" /></DRUG1>
<DRUG2>
<DRUG name="HALOFANTRINE" rxcui="50749">
<ATC code="P01BX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmia, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If it is possible, interrupt the azole antifungal. If administering the substances together cannot be avoided, testing of the QT before the beginning of the treatment and EKG monitoring</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>57-AZOLE-ANTIFUNGALS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="AZOLE ANTIFUNGALS" code="J02AC-001" /></DRUG1>
<DRUG2>
<DRUG name="MIDAZOLAM" rxcui="6960">
<ATC code="N05CD08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation

.</DESCRIPTION>
<SEVERITY>Precaution for use with:</SEVERITY>
<COMMENT>-midazolam IV route</COMMENT>
</INTERACTION>
</INTERACTIONS>
